{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:39:58Z","timestamp":1786466398634,"version":"build-2736575974"},"reference-count":31,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The impact of fludarabine pharmacokinetics (PK) on chimeric antigen receptor (CAR) T-cell outcomes is not fully elucidated. We hypothesized that in patients with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL), measured fludarabine exposure during lymphodepletion would correlate with CAR T-cell results. We conducted a prospective, single-center study including patients with R\/R LBCL treated with commercial, CD19-targeted CAR T-cell products. Up to 7 plasma samples per patient were collected at predefined intervals during lymphodepletion. Fludarabine exposure (area under the curve [AUC]) was estimated using a population PK model. An iterative cubic spline approach identified optimal AUC exposure ranges specific to each CAR T-cell product. The primary end point was progression-free survival (PFS). Among 54 patients with a median follow-up of 24.5 months, the median fludarabine AUC was 18.12 mg\u00b7h\/L (interquartile range, 14.56-20.55). Optimal exposure windows were 17.5 to 21.5 mg\u00b7h\/L for axicabtagene ciloleucel (axi-cel) and 14.0 to 18.0 mg\u00b7h\/L for tisagenlecleucel, with 24 patients (44%) inside these ranges. Median PFS after CAR T-cell infusion was not reached vs 13.3 months in the optimal vs other cohort (P = .03). In the multivariable analysis, optimal exposure remained independently associated with improved PFS (P = .03), together with axi-cel treatment (P = .03). CAR T-cell expansion and rates of any grade cytokine release syndrome, immune effector cell\u2013associated neurotoxicity syndrome, and hematotoxicity were similar between groups. In conclusion, the prospective measurement of fludarabine exposure identified an optimal AUC window associated with prolonged PFS in patients with R\/R LBCL receiving CAR T-cell therapy. These findings support the integration of PK-guided fludarabine dosing to enhance therapeutic outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019264","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T18:53:52Z","timestamp":1781117632000},"page":"5460-5468","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2301-1367","authenticated-orcid":false,"given":"Mario Andr\u00e9s","family":"S\u00e1nchez-Salinas","sequence":"first","affiliation":[{"name":"1Department of Hematology, Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"2Department of Medicine, Universitat Aut\u00f2noma of Barcelona, Bellaterra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Varela-Gonz\u00e1lez-Aller","sequence":"additional","affiliation":[{"name":"3Department of Pharmacy, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"4Catalan Institute of Oncology - Hospitalet, Pharmacy, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0805-9288","authenticated-orcid":false,"given":"Gloria","family":"Iacoboni","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"2Department of Medicine, Universitat Aut\u00f2noma of Barcelona, Bellaterra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-4605","authenticated-orcid":false,"given":"V\u00edctor","family":"Navarro","sequence":"additional","affiliation":[{"name":"5Oncology Data Science Group, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3700-8658","authenticated-orcid":false,"given":"I\u00f1aki","family":"Troconiz","sequence":"additional","affiliation":[{"name":"6Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9346-0134","authenticated-orcid":false,"given":"Cecilia","family":"Carpio","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"2Department of Medicine, Universitat Aut\u00f2noma of Barcelona, Bellaterra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Alonso-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"3Department of Pharmacy, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6482-9940","authenticated-orcid":false,"given":"Maria-Josep","family":"Carreras-Soler","sequence":"additional","affiliation":[{"name":"3Department of Pharmacy, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4843-4858","authenticated-orcid":false,"given":"Anna","family":"Farriols-Danes","sequence":"additional","affiliation":[{"name":"3Department of Pharmacy, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Guerra-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"3Department of Pharmacy, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Rivas-Delgado","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Rivera","sequence":"additional","affiliation":[{"name":"3Department of Pharmacy, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Feijoo","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Bosch","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"2Department of Medicine, Universitat Aut\u00f2noma of Barcelona, Bellaterra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Valdivia","sequence":"additional","affiliation":[{"name":"3Department of Pharmacy, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Miarons","sequence":"additional","affiliation":[{"name":"3Department of Pharmacy, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"7Department of Pharmacy, Consorci Hospitalari de Vic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7076-7969","authenticated-orcid":false,"given":"Pere","family":"Barba","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"2Department of Medicine, Universitat Aut\u00f2noma of Barcelona, Bellaterra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"1","key":"2026081110263639600_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"2026081110263639600_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2026081110263639600_bib3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","article-title":"A national service for delivering CD19 CAR-Tin large B-cell lymphoma - the UK real-world experience","volume":"198","author":"Kuhnl","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"2026081110263639600_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica"},{"issue":"27","key":"2026081110263639600_bib5","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"22","key":"2026081110263639600_bib6","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2026081110263639600_bib7","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00277-021-04560-6","article-title":"Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy","volume":"100","author":"Iacoboni","year":"2021","journal-title":"Ann Hematol"},{"issue":"19","key":"2026081110263639600_bib8","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"2026081110263639600_bib9","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/bloodadvances.2020003959","article-title":"Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting","volume":"5","author":"Ayuk","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2026081110263639600_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12139","article-title":"Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells","volume":"257","author":"Jensen","year":"2014","journal-title":"Immunol Rev"},{"issue":"355","key":"2026081110263639600_bib11","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"2","key":"2026081110263639600_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol"},{"issue":"1","key":"2026081110263639600_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0b013e3181b88ffc","article-title":"Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells","volume":"33","author":"Wrzesinski","year":"2010","journal-title":"J Immunother"},{"issue":"17","key":"2026081110263639600_bib14","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"14","key":"2026081110263639600_bib15","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/bloodadvances.2018029421","article-title":"Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes","volume":"3","author":"Langenhorst","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"2026081110263639600_bib16","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"7","key":"2026081110263639600_bib17","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2026081110263639600_bib18","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","article-title":"Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia","volume":"6","author":"Dekker","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2026081110263639600_bib19","first-page":"989","article-title":"Fludarabine lymphodepletion exposure is associated with toxicities after idecabtagene-vicleucel in relapsed\/refractory multiple myeloma: real-world experience from the US Myeloma Immunotherapy Consortium","volume":"31","author":"Sweiss","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"18","key":"2026081110263639600_bib20","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1182\/bloodadvances.2023010302","article-title":"Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma","volume":"7","author":"Scordo","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2026081110263639600_bib21","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1182\/bloodadvances.2023011433","article-title":"Is estimated exposure an accurate surrogate for measured fludarabine levels in CAR T-cell patients?","volume":"8","author":"S\u00e1nchez-Salinas","year":"2024","journal-title":"Blood Adv"},{"key":"2026081110263639600_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.trsl.2016.03.017","article-title":"Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning","volume":"175","author":"Sanghavi","year":"2016","journal-title":"Transl Res"},{"issue":"4","key":"2026081110263639600_bib23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"2026081110263639600_bib24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2026081110263639600_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026081110263639600_bib26","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00228-024-03751-0","article-title":"The impact of age and renal function on the pharmacokinetics and protein binding characteristics of fludarabine in paediatric and adult patients undergoing allogeneic haematopoietic stem cell transplantation conditioning","volume":"80","author":"Nath","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"issue":"16","key":"2026081110263639600_bib27","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1158\/1078-0432.CCR-09-0427","article-title":"A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients","volume":"15","author":"Salinger","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026081110263639600_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00280-014-2618-2","article-title":"Population pharmacokinetic\/dynamic model of lymphosuppression after fludarabine administration","volume":"75","author":"McCune","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"2026081110263639600_bib29","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3390\/pharmaceutics17121592","article-title":"Towards personalized lymphodepletion: a population pharmacokinetic fludarabine model in patients receiving CAR T-cell therapy","volume":"17","author":"Varela-Gonz\u00e1lez-Aller","year":"2025","journal-title":"Pharmaceutics"},{"issue":"27","key":"2026081110263639600_bib30","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026081110263639600_bib31","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40262-018-0715-9","article-title":"Population pharmacokinetics of fludarabine in children and adults during conditioning prior to allogeneic hematopoietic cell transplantation","volume":"58","author":"Langenhorst","year":"2019","journal-title":"Clin Pharmacokinet"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5460\/2536702\/blooda_adv-2025-019264-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5460\/2536702\/blooda_adv-2025-019264-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:43:11Z","timestamp":1786462991000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/15\/5460\/569081\/Impact-of-fludarabine-exposure-on-CAR-T-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":31,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019264","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,11]]},"published":{"date-parts":[[2026,8,3]]}}}